06 January 2017

C4X Discovery Holdings plc - Full year results for the year ended 31 July 2016


6 January 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its full year results for the year ended 31 July 2016. 

Financial highlights 

  • Fee-for-service revenue for the 12 months ended 31 July 2016 was £279,000 (2015: £312,000).
  • Loss after tax for the 12 months ended 31 July 2016 was £5,321,000 or 16.83 pence per share (2015: £3,064,000 or 10.77 pence per share).
  • R&D expenses increased by 66% to £5,239,000 for the year ended 31 July 2016 (2015: £3,159,000).
  • Administrative expenses increased by £903,000 during the year to £1,817,000 (2015: £904,000).
  • Net assets at 31 July 2016 of £4,305,000 (2015: £7,968,000).
  • Cash, cash equivalents, short-term investments and deposits of £1,328,000 (2015: £7,485,000).

Strategic and Operational highlights

Strategy

  • The Board has committed to the delivery of C4X Discovery’s (“C4XD”) vision to become the world’s most productive Drug Discovery Engine. Focus has shifted to generating a high value pre-clinical asset portfolio that will drive revenue through early stage licensing deals. Existing fee-for-service agreements have been discontinued after the year end.
  • Strategic acquisitions made to enhance the Company’s core target identification and drug design capabilities:
    • In March 2016, Adorial Limited (“Adorial”) together with its subsidiaries and its proprietary DNA based target identification platform, Taxonomy3®, were acquired. New Taxonomy3® targets in rheumatoid arthritis were announced in July 2016 alongside a potential personalised medicine approach in Parkinson’s disease; and
    • In July 2016, the pioneering computational drug discovery technologies from MolPlex Ltd were acquired, further enhancing the Company’s cutting-edge drug design platform.

Senior appointments

  • Dr Clive Dix was appointed Chief Executive Officer in May 2016, following a successful period as Executive Chairman

Discovery Engine progress

  • Drug asset portfolio grown from three programmes in addiction, diabetes and chronic obstructive pulmonary disorder at the time of the IPO in 2014 to eight programmes across a number of therapeutic areas.
    • Future disease areas of focus will be inflammation, neurodegeneration and other areas selected on an opportunistic basis, for example, mmune-oncology.

Partnerships/acquisitions 

  • In October 2015, a new research collaboration was announced with the University of Oxford’s Structural Genomics Consortium, providing C4XD with access to valuable target, assay and ‘hit’ molecule information.
  • Acquisition of Adorial Limited and its subsidiaries (“Adorial”) on 1 March 2016 for £1,670,700.

Post-period end 

  • Completion of a £5.0 million fundraise in September 2016 through the conditional placing of 4,901,961 new ordinary shares at a price of 102 pence per ordinary share.
  • A new multi-target risk-sharing alliance with Evotec AG (“Evotec”) was announced in September 2016. Evotec and C4XD will work together on novel small molecule drugs across a range of targets, therapeutic areas and stages of development.
  • Brad Hoy, Chief Financial Officer, and Dr Craig Fox, Chief Scientific Officer, were appointed to the Board of Directors in November 2016 

“In this period, C4X Discovery has taken significant steps towards our vision of becoming the world’s most productive Drug Discovery Engine. We have acquired new technologies to enhance our core target identification and drug design capabilities, expanded our drug asset portfolio and signed new strategic alliances to support our core expertise in solving the drug discovery challenges that confound others. “We have defined our strategy to drive revenue through early-stage licensing deals around a high value, pre-clinical portfolio. In the coming year, we will focus on securing deal revenue from our existing portfolio, progressing our discovery candidates to pre-clinical development, identifying novel and exciting drug targets and selectively building our operations to support our vision. I believe C4X Discovery has the team in place to deliver this strategy.”

Dr Clive Dix

CEO of C4X Discovery

A copy of the final results presentation given by Clive Dix (Chief Executive Officer) and Brad Hoy (Chief Financial Officer) will be released later this morning on the Group’s website at www.c4xdiscovery.com

Analyst conference call today

Dr Clive Dix, Chief Executive Officer, will present the results at 14:00pm GMT on 6 January 2017 during a live conference call. Dial-in details are:

Participant local dial-in: +44(0)20 31394830

Participant free phone dial-in: 08082370030

Participant code: 72026171#

A live webcast of the meeting, with presentation slides will be available on C4X Discovery’s website.

To register for the webcast:

http://arkadinemea-events.adobeconnect.com/c4x_discovery_results/event/registration.html

In accordance with AIM Rule 20, electronic copies of its Annual Report and Accounts for the year ended 31 July 2016, together with the Notice of Annual General Meeting and Form of Proxy are available from the Company’s website at www.c4xdiscovery.com. Hard copies of the 2016 Annual Report and Accounts, Notice of Annual General Meeting and Form of Proxy will be posted to shareholders today.

The Company’s Annual General Meeting will be held at 12.00 noon on Tuesday, 31 January 2017 at The Podium, Euston, 1 Eversholt Street, London NW1 1AD.

For further information, please contact:

C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer
07801 865 803

Zeus Capital Limited
Dan Bate: 0161 831 1512                                                                                                                               
Dominic Wilson/Phil Walker: 0203 829 5000

Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner
0203 709 5700 

About C4X Discovery

C4X Discovery aims to become the world’s most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company’s goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company’s innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X’s novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from other areas selected on an opportunistic basis, for example, mmune-oncology.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO.For additional information please go to: www.c4xdiscovery.com


Back to previous page